Intrexon Corporation (NYSE:XON) was the recipient of unusually large options trading on Friday. Traders acquired 2,236 put options on the stock. This represents an increase of approximately Infinity compared to the typical volume of 0 put options.
Intrexon Corporation (XON) opened at $11.81 on Monday. Intrexon Corporation has a 52-week low of $11.80 and a 52-week high of $32.90. The company has a current ratio of 2.45, a quick ratio of 2.25 and a debt-to-equity ratio of 0.01.
In other Intrexon Corporation news, Director Robert B. Shapiro purchased 2,850 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was purchased at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares of the company’s stock, valued at $755,247.50. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 55.10% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in shares of Intrexon Corporation by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after acquiring an additional 4,937 shares in the last quarter. Federated Investors Inc. PA purchased a new position in shares of Intrexon Corporation in the second quarter valued at about $172,000. SG Americas Securities LLC purchased a new position in shares of Intrexon Corporation in the third quarter valued at about $139,000. Cullinan Associates Inc. purchased a new position in shares of Intrexon Corporation in the second quarter valued at about $201,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Intrexon Corporation in the second quarter worth about $212,000. Institutional investors and hedge funds own 82.10% of the company’s stock.
Several brokerages recently commented on XON. Bank of America Corporation cut their price objective on Intrexon Corporation from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday. Stifel Nicolaus lifted their price objective on Intrexon Corporation from $39.00 to $57.00 and gave the stock a “buy” rating in a report on Friday. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Intrexon Corporation in a report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Intrexon Corporation has a consensus rating of “Hold” and an average price target of $38.50.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.